Adhesion molecule CD146 and its soluble form correlate well with carotid atherosclerosis and plaque instability

CNS Neuroscience and Therapeutics

Volumn 20, Issue 5, 2014, Pages 438-445

  Qian, Yi Ning ^a   Luo, Yong Ting ^b   Duan, Hong Xia ^b   Feng, Li Qun ^a   Bi, Qi ^a   Wang, Yong Jun ^c   Yan, Xi Yun ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TOKYO   (Japan)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adhesion molecule CD146; Atherosclerosis; Plaque instability

Indexed keywords

C REACTIVE PROTEIN; CD146 ANTIGEN; CELL ADHESION MOLECULE; GELATINASE B; MCAM PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; BLOOD VESSEL; CARDIAC PATIENT; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOAM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEOVASCULARIZATION (PATHOLOGY); PROTEIN EXPRESSION; BLOOD; CAROTID ARTERY DISEASES; ECHOGRAPHY; MACROPHAGE; METABOLISM; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

AGED; ANTIGENS, CD146; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC;

EID: 84899107499     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12234     Document Type: Article

References (50)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-2138.
3. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010;30:1282-1292.
4. Rothwell PM. Carotid artery disease and the risk of ischaemic stroke and coronary vascular events. Cerebrovasc Dis 2000;10(Suppl 5):21-33.
5. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006;47:C13-C18.
6. Pelisek J, Rudelius M, Zepper P, et al. Multiple biological predictors for vulnerable carotid lesions. Cerebrovasc Dis 2009;28:601-610.
7. Heider P, Pelisek J, Poppert H, Eckstein HH. Evaluation of serum matrix metalloproteinases as biomarkers for detection of neurological symptoms in carotid artery disease. Vasc Endovascular Surg 2009;43:551-560.
8. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003;59:812-823.
9. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994;8:504-512.
10. Zernecke A, Weber C. Inflammatory mediators in atherosclerotic vascular disease. Basic Res Cardiol 2005;100:93-101.
11. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101.
12. Inoue M, Ishida T, Yasuda T, et al. Endothelial cell-selective adhesion molecule modulates atherosclerosis through plaque angiogenesis and monocyte-endothelial interaction. Microvasc Res 2010;80:179-187.
13. McEver RP. Selectins: lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 2002;14:581-586.
14. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96:4219-4225.
15. Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001;358:971-976.
16. Schlagbauer-Wadl H, Jansen B, Muller M, et al. Influence of MUC18/MCAM/CD146 expression on human melanoma growth and metastasis in SCID mice. Int J Cancer 1999;81:951-955.
17. Jiang T, Zhuang J, Duan H, et al. CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 2012;120:2330-2339.
18. Yan X, Lin Y, Yang D, et al. A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth. Blood 2003;102:184-191.
19. Bardin N, Reumaux D, Geboes K, et al. Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease. Inflamm Bowel Dis 2006;12:16-21.
20. Li L, Zhang BR, Zeng XF, Wang X. A pilot study on the significance of leucocyte CD146 expression in vasculitisZhonghua Nei Ke Za Zhi 2006;45:748-751.
21. Duan H, Xing S, Luo Y, et al. Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS. Sci Rep 2013;3:1687.
22. Bardin N, Moal V, Anfosso F, et al. Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost 2003;90:915-920.
23. Duan H, Luo Y, Hao H, et al. Soluble CD146 in cerebrospinal fluid of active multiple sclerosis. Neuroscience 2013;235:16-26.
24. Figarella-Branger D, Schleinitz N, Boutiere-Albanese B, et al. Platelet-endothelial cell adhesion molecule-1 and CD146: soluble levels and in situ expression of cellular adhesion molecules implicated in the cohesion of endothelial cells in idiopathic inflammatory myopathies. J Rheumatol 2006;33:1623-1630.
25. Reumaux D, Bardin N, Colombel JF, Dignat-George F, Duthilleul P, Vermeire S. Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF-alpha antagonist infliximab. Inflamm Bowel Dis 2007;13:1315-1317.
26. Geroulakos G, Ramaswami G, Nicolaides A, et al. Characterization of symptomatic and asymptomatic carotid plaques using high-resolution real-time ultrasonography. Br J Surg 1993;80:1274-1277.
27. Zhang Y, Zheng C, Zhang J, et al. Generation and characterization of a panel of monoclonal antibodies against distinct epitopes of human CD146. Hybridoma (Larchmt) 2008;27:345-352.
28. Zheng C, Qiu Y, Zeng Q, et al. Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol 2009;41:2163-2172.
29. George SJ. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 2000;9:993-1007.
30. Vora DK, Fang ZT, Liva SM, et al. Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res 1997;80:810-818.
31. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995;95:1262-1270.
32. Ballantyne CM, Entman ML. Soluble adhesion molecules and the search for biomarkers for atherosclerosis. Circulation 2002;106:766-767.
33. Guray U, Erbay AR, Guray Y, et al. Levels of soluble adhesion molecules in various clinical presentations of coronary atherosclerosis. Int J Cardiol 2004;96:235-240.
34. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005;112:976-983.
35. Fleiner M, Kummer M, Mirlacher M, et al. Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation 2004;110:2843-2850.
36. McCarthy MJ, Loftus IM, Thompson MM, et al. Angiogenesis and the atherosclerotic carotid plaque: an association between symptomatology and plaque morphology. J Vasc Surg 1999;30:261-268.
37. Moreno PR, Purushothaman KR, Fuster V, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110:2032-2038.
38. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94:2013-2020.
39. Kolodgie F D, Narula J, Haider N, Virmani R. Apoptosis in atherosclerosis. Does it contribute to plaque instability? Cardiol Clin 2001;19:127-139, ix.
40. Kuge Y, Takai N, Ishino S, Temma T, Shiomi M, Saji H. Distribution profiles of membrane Type-1 matrix metalloproteinase (MT1-MMP), matrix metalloproteinase-2 (MMP-2) and cyclooxygenase-2 (COX-2) in rabbit atherosclerosis: comparison with plaque instability analysis. Biol Pharm Bull 2007;30:1634-1640.
41. Newby AC, Libby P, van der Wal AC. Plaque instability-the real challenge for atherosclerosis research in the next decade? Cardiovasc Res 1999;41:321-322.
42. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol 2009;218:7-29.
43. Krupinski J, Font A, Luque A, Turu M, Slevin M. Angiogenesis and inflammation in carotid atherosclerosis. Front Biosci 2008;13:6472-6482.
44. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr Vasc Pharmacol 2005;3:63-68.
45. Briley-Saebo KC, Cho YS, Tsimikas S. Imaging of oxidation-specific epitopes in atherosclerosis and macrophage-rich vulnerable plaques. Curr Cardiovasc Imaging Rep 2011;4:4-16.
46. Wagsater D, Zhu C, Bjorkegren J, Skogsberg J, Eriksson P. MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse. Int J Mol Med 2011;28:247-253.
47. Boneberg EM, Illges H, Legler DF, Furstenberger G. Soluble CD146 is generated by ectodomain shedding of membrane CD146 in a calcium-induced, matrix metalloprotease-dependent process. Microvasc Res 2009;78:325-331.
48. Harhouri K, Kebir A, Guillet B, et al. Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 2010;115:3843-3851.
49. Garibaldi S, Barisione C, Ghigliotti G, et al. Soluble form of the endothelial adhesion molecule CD146 binds preferentially CD16 + monocytes. Mol Biol Rep 2012;39:6745-6752.
50. Bardin N, Blot-Chabaud M, Despoix N, et al. CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler Thromb Vasc Biol 2009;29:746-753.